Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.32 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.31 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28066788 | 0.97 | FFAR4 (0.43) | FFAR4FFAR1NFKB1GPR84LMNA | |
| SCHEMBL5030141 | 0.94 | FFAR4 (0.45) | FFAR4FFAR1NFKB1GPR84LMNA | |
| SCHEMBL30787309 | 0.92 | FFAR1 (0.48) | FFAR4FFAR1NFKB1GPR84FDPS | |
| SCHEMBL30787248 | 0.92 | FFAR1 (0.48) | FFAR4FFAR1NFKB1GPR84FDPS | |
| SCHEMBL27535858 | 0.92 | FFAR1 (0.48) | FFAR4FFAR1NFKB1GPR84FDPS | |
| SCHEMBL29786725 | 0.92 | FFAR1 (0.48) | FFAR4FFAR1NFKB1GPR84FDPS | |
| SCHEMBL10053633 | 0.92 | FFAR1 (0.48) | FFAR4FFAR1NFKB1GPR84FDPS | |
| SCHEMBL30787192 | 0.92 | FFAR1 (0.48) | FFAR4FFAR1NFKB1GPR84FDPS | |
| 3-Heptanol SCHEMBL2882446 | 0.92 | FFAR4 (0.43) | FFAR4FFAR1NFKB1GPR84FDPS | |
| SCHEMBL15102903 | 0.91 | FFAR4 (0.39) | FFAR4FFAR1NFKB1GPR84LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6899753-B2 | Highly bleed-alleviating ink composition | BENQ CORPORATION (TW) | 2005-05-31 | — | — | US | claimed |
| US-20030037700-A1 | Highly bleed-alleviating ink composition | MIND FUSION, LLC | 2003-02-27 | — | — | US | claimed |
| EP-3194371-B1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY SCIENCE TECH & RES (SG) | 2020-09-02 | — | — | EP | disclosed |
| US-10570097-B2 | Antimicrobial imidazolium compounds | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-02-25 | — | — | US | disclosed |
| US-20190016684-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-01-17 | — | — | US | disclosed |
| US-10160728-B2 | Antimicrobial imidazolium compounds | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-12-25 | — | — | US | disclosed |
| US-20170291877-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-10-12 | — | — | US | disclosed |
| EP-2700636-B1 | PROCESS FOR PREPARING EPISULFIDE COMPOUNDS | ASAHI CHEMICAL IND (JP) | 2017-08-02 | — | — | EP | disclosed |
| EP-3194371-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | Agency for Science, Technology and Research (SG) | 2017-07-26 | — | — | EP | disclosed |
| US-9359324-B2 | Process for preparing episulfide compounds | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-06-07 | — | — | US | disclosed |
| WO-2016043660-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-03-24 | — | — | WO | disclosed |
| CN-101519552-B | Method for preparing inkjet water-soluble ink containing noble metal nano particles | CHINESE ACAD INST CHEMISTRY | 2011-08-24 | — | — | CN | disclosed |
| CN-101519552-A | Method for preparing inkjet water-soluble ink containing noble metal nano particles | CHINESE ACAD INST CHEMISTRY | 2009-09-02 | — | — | CN | disclosed |
| US-6899753-B2 | Highly bleed-alleviating ink composition | BENQ CORPORATION (TW) | 2005-05-31 | — | — | US | disclosed |
| CN-1401710-A | Ink composition with high ink bleeding prevention | BENQ CORP (CN) | 2003-03-12 | — | — | CN | disclosed |
| US-20030037700-A1 | Highly bleed-alleviating ink composition | MIND FUSION, LLC | 2003-02-27 | — | — | US | disclosed |
| US-6130152-A | Aerogel thin film formation from multi-solvent systems | TEXAS INSTRUMENTS INCORPORATED (US) | 2000-10-10 | — | — | US | disclosed |
| EP-0225044-B1 | PEPTIC ULCER TREATMENT | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-08-28 | — | — | EP | disclosed |
| US-4707495-A | PROSTAGLANDINS | ORTHO PHARMACEUTICAL (US) | 1987-11-17 | — | — | US | disclosed |
| EP-0225044-A1 | Peptic ulcer treatment | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570097-B2 | Antimicrobial imidazolium compounds | CCNI, MACF1, ECI1 | FFAR4 2701/4885FFAR1 1885/4885NFKB1 639/4885 |
| US-10160728-B2 | Antimicrobial imidazolium compounds | CCNI, MACF1, ECI1 | FFAR4 2701/4885FFAR1 1885/4885NFKB1 639/4885 |
| US-20170291877-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | CCNI, MACF1, ECI1 | FFAR4 2701/4885FFAR1 1885/4885NFKB1 639/4885 |
| US-20190016684-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | CCNI, MACF1, ECI1 | FFAR4 2701/4885FFAR1 1885/4885NFKB1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.